Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
Daxor Corporation - Closed End Fund (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: GlobeNewswire
Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA). As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification of a patient’s total blood, plasma, and red cell volume, the BVA replaces subjective guesswork with definitive data. This precision is a critical benefit of BVA, particularly for health systems navigating the $3.5 billion annual Medicare burden of heart failure readmissions in the United States. “The most expensive patient is the one who comes back,” said Michael Feldschuh, Daxor CEO and President. “Our BVA system replaces clinical guesswork with objective data, allowing teams to optimize fluid management and discharge
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation - Closed End Fund news events
Weekly update
A roundup of the hottest topics
DXR
News
- Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions [Yahoo! Finance]Yahoo! Finance
- Daxor Details Portable FDA-Cleared Blood Volume Analyzer, 'Razor-and-Blades' Kit Growth at iAccess Alpha [Yahoo! Finance]Yahoo! Finance
- Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
- Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress [Yahoo! Finance]Yahoo! Finance
- Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care CongressGlobeNewswire
DXR
Sec Filings
- 3/16/26 - Form N-CEN
- 3/2/26 - Form N-CSR
- 3/2/26 - Form NPORT-P
- DXR's page on the SEC website